Table 4.
Association of VKORC1 and CYP2C9 SNPs with warfarin response during the stabilization phase of therapy of 139 cardiovascular patients treated with warfarin.
| Gene | SNP ID | Genotype | Poor respondera | Good responderb | Ultra responderc | P-value* |
|---|---|---|---|---|---|---|
| VKORC1 | rs10871454 | CC | (0/28) 0.0% | (27/28) 96.4% | (1/28) 3.6% | 0.621 |
| CT | (6/69) 8.7% | (60/69) 87.0% | (3/69) 4.3% | |||
| TT | (3/42) 7.1% | (37/42) 88.1% | (2/42) 4.8% | |||
| rs8050894 | CC | (0/26) 0.0% | (25/26) 96.2% | (1/26) 3.8% | 0.659 | |
| CG | (6/69) 8.7% | (60/69) 87% | (3/69) 4.3% | |||
| GG | (3/44) 6.8% | (39/44) 88.6% | (2/44) 4.5% | |||
| rs9934438 | CC | (0/28) 0.0% | (27/28) 96.4% | (1/28) 3.6% | 0.527 | |
| CT | (6/71) 8.6% | (61/71) 85.9% | (4/71) 5.5% | |||
| TT | (3/40) 7.5% | (36/40) 90.0% | (1/40) 2.5% | |||
| rs17708472 | CC | (6/106) 5.7% | (94/106) 88.7% | (6/106) 5.6% | 0.593 | |
| CT | (3/30) 10.0% | (27/30) 90.0% | (0/0) 0.0% | |||
| TT | (0/3) 0.0% | (3/3) 100.0% | 0.0% | |||
| CYP2C9 | rs1799853 | CC | (8/105) 7.6% | (93/105) 88.6% | (4/105) 3.8% | 0.851 |
| CT | (1/32) 3.1% | (29/32) 90.6% | (2/32) 6.3% | |||
| TT | (0.0) 0.0% | (2/2) 100.0% | 0.0% | |||
| rs4086116 | CC | (6/77) 7.8% | (68/77) 88.3% | (3/77) 3.9% | 0.806 | |
| CT | (3/53) 5.7% | (47/53) 88.6% | (3/53) 5.7% | |||
| TT | (0/9) 0.0% | (9/9) 100.0% | 0.0% | |||
| rs1057910 | AA | (8/108) 7.4% | (94/108) 87.0% | (6/108) 5.6% | 0.269 | |
| AC | (1/31) 3.2% | (30/31) 96.8% | 0.0% | |||
*
Chi-Square Test with p value < 0.05 is considered significant.
a
Poor responders (INR value below target).
b
Good responders who have an INR value in the target range (therapeutic range).
c
Ultra responders (INR over target).